Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model

Journal of the American Society of Nephrology

Volumn 26, Issue 1, 2015, Pages 39-47

  Hopp, Katharina ^a   Hommerding, Cynthia J ^a   Wang, Xiaofang ^a   Ye, Hong ^a   Harris, Peter C ^a,b   Torres, Vicente E ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; DESMOPRESSIN; PASIREOTIDE; TOLVAPTAN; ANTIDIURETIC AGENT; ARGIPRESSIN[1 DEAMINO]; BENZAZEPINE DERIVATIVE; MICROSATELLITE DNA; POLYCYSTIC KIDNEY DISEASE 1 PROTEIN; POLYCYSTIN; SOMATOSTATIN; VASOPRESSIN RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG POTENTIATION; KIDNEY POLYCYSTIC DISEASE; LIVER HYPERTROPHY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; CELL MEMBRANE; COMBINATION DRUG THERAPY; DISEASE MODEL; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIDIURETIC AGENTS; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; BENZAZEPINES; CELL LINE, TUMOR; CELL MEMBRANE; CYCLIC AMP; DEAMINO ARGININE VASOPRESSIN; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROSATELLITE REPEATS; MODELS, GENETIC; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; SOMATOSTATIN; TRPP CATION CHANNELS;

EID: 84924168225     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013121312     Document Type: Article

References (37)

1. Harris PC, Torres VE: Polycystic kidney disease, autosomal dominant. In: GeneReviews, edited by Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, Seattle, University of Washington, 1993 [Updated 2011]
2. Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney disease. Lancet 369: 1287-1301, 2007
3. Nauli SM, Alenghat FJ, Luo Y, Williams E, Vassilev P, Li X, Elia AE, Lu W, Brown EM, Quinn SJ, Ingber DE, Zhou J: Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 33: 129-137, 2003
4. Kusano E, Murayama N, Werness JL, Christensen S, Homma S, Yusufi AN, Dousa TP: Effects of calcium on the vasopressin-sensitive cAMP metabolism in medullary tubules. Am J Physiol 249: F956-F966, 1985
5. Kusano E, Yoshida I, Takeda S, Homma S, Yusufi AN, Dousa TP, Asano Y: Nephron distribution of total low Km cyclic AMP phosphodiesterase in mouse, rat and rabbit kidney. Tohoku J Exp Med 193: 207-220, 2001
6. Chabardès D, Imbert-Teboul M, Elalouf JM: Functional properties of Ca2+-inhibitable type 5 and type 6 adenylyl cyclases and role of Ca2+ increase in the inhibition of intracellular cAMP content. Cell Signal 11: 651-663, 1999
7. Yamaguchi T, Nagao S, Kasahara M, Takahashi H, Grantham JJ: Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis 30: 703-709, 1997
8. Gattone VH 2nd, Wang X, Harris PC, Torres VE: Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9: 1323-1326, 2003
9. Smith LA, Bukanov NO, Husson H, Russo RJ, Barry TC, Taylor AL, Beier DR, Ibraghimov-Beskrovnaya O: Development of polycystic kidney disease in juvenile cystic kidney mice: Insights into pathogenesis, ciliary abnormalities, and common features with human disease. J Am Soc Nephrol 17: 2821-2831, 2006
10. Starremans PG, Li X, Finnerty PE, Guo L, Takakura A, Neilson EG, Zhou J: A mouse model for polycystic kidney disease through a somatic in-frame deletion in the 5′ end of Pkd1. Kidney Int 73: 1394-1405, 2008
11. Hopp K, Ward CJ, Hommerding CJ, Nasr SH, Tuan HF, Gainullin VG, Rossetti S, Torres VE, Harris PC: Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. J Clin Invest 122: 4257-4273, 2012
12. Yamaguchi T, Pelling JC, Ramaswamy NT, Eppler JW, Wallace DP, Nagao S, Rome LA, Sullivan LP, Grantham JJ: cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 57: 1460-1471, 2000
13. Hanaoka K, Guggino WB: cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol 11: 1179-1187, 2000
14. Torres VE, Harris PC: Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol 25: 18-32, 2014
15. Chabardès D, Firsov D, Aarab L, Clabecq A, Bellanger AC, Siaume-Perez S, Elalouf JM: Localization of mRNAs encoding Ca2+-inhibitable adenylyl cyclases along the renal tubule. Functional consequences for regulation of the cAMP content. J Biol Chem 271: 19264-19271, 1996
16. Strait KA, Stricklett PK, Chapman M, Kohan DE: Characterization of vasopressin-responsive collecting duct adenylyl cyclases in themouse. Am J Physiol Renal Physiol 298: F859-F867, 2010
17. Rieg T, Tang T, Murray F, Schroth J, Insel PA, Fenton RA, Hammond HK, Vallon V: Adenylate cyclase 6 determines cAMP formation and aquaporin-2 phosphorylation and trafficking in inner medulla. J Am Soc Nephrol 21: 2059-2068, 2010
18. Gattone VH 2nd, Maser RL, Tian C, Rosenberg JM, Branden MG: Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev Genet 24: 309-318, 1999
19. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd: Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 10: 363-364, 2004
20. Wang X, Gattone V 2nd, Harris PC, Torres VE: Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 16: 846-851, 2005
21. Meijer E, Gansevoort RT, de Jong PE, van der Wal AM, Leonhard WN, de Krey SR, van den Born J, Mulder GM, van Goor H, Struck J, de Heer E, Peters DJ: Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug. Nephrol Dial Transplant 26: 2445-2453, 2011
22. Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS; TEMPOFormula and 156-05-002 Study Investigators: Tolvaptan in autosomal dominant polycystic kidney disease: Three years' experience. Clin J Am Soc Nephrol 6: 2499-2507, 2011
23. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators: Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367: 2407-2418, 2012
24. Friedlander G, Amiel C: Somatostatin and alpha 2-adrenergic agonists selectively inhibit vasopressin-induced cyclic AMP accumulation in MDCK cells. FEBS Lett 198: 38-42, 1986
25. Ishikawa S, Saito T, Kuzuya T: Reversal of somatostatin inhibition of AVP-induced cAMP by pertussis toxin. Kidney Int 33: 536-542, 1988
26. Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF: Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3′,5′-cyclic monophosphate. Gastroenterology 132: 1104-1116, 2007
27. Masyuk TV, Radtke BN, Stroope AJ, Banales JM, Gradilone SA, Huang B, Masyuk AI, Hogan MC, Torres VE, Larusso NF: Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology 58: 409-421, 2013
28. Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene-Iordache B, Remuzzi G, Epstein FH: Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 68: 206-216, 2005
29. van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, de Man RA, Drenth JP: Lanreotide reduces the volume of polycystic liver: A randomized, double-blind, placebo-controlled trial. Gastroenterology 137: 1661-1668, 2009
30. Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, Kim B, King BF, Glockner J, Holmes DR 3rd, Rossetti S, Harris PC, LaRusso NF, Torres VE: Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 21: 1052-1061, 2010
31. Caroli A, Perico N, Perna A, Antiga L, Brambilla P, Pisani A, Visciano B, Imbriaco M, Messa P, Cerutti R, Dugo M, Cancian L, Buongiorno E, De Pascalis A, Gaspari F, Carrara F, Rubis N, Prandini S, Remuzzi A, Remuzzi G, Ruggenenti P; ALADIN study group: Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): A randomised, placebo-controlled, multicentre trial. Lancet 382: 1485-1495, 2013
32. Walker BJ, Evans PA, Forsling ML, Nelstrop GA: Somatostatin and water excretion in man: an intrarenal action. Clin Endocrinol (Oxf) 23: 169-174, 1985
33. Vora JP, Owens DR, Ryder R, Atiea J, Luzio S, Hayes TM: Effect of somatostatin on renal function. Br Med J (Clin Res Ed) 292: 1701-1702, 1986
34. Reynaert H, Rombouts K, Vandermonde A, Urbain D, Kumar U, Bioulac-Sage P, Pinzani M, Rosenbaum J, Geerts A: Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut 53: 1180-1189, 2004
35. Liu HL, Huo L, Wang L: Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells. Acta Pharmacol Sin 25: 1380-1386, 2004
36. Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, Li J, King BF, Martin D, Wetzel LH, Lockhart ME, Harris PC, Moxey-Mims M, Flessner M, Bennett WM, Grantham JJ: Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 7: 479-486, 2012
37. Wang X, Ye H, Ward CJ, Chu JY, Masyuk TV, Larusso NF, Harris PC, Chow BK, Torres VE: Insignificant effect of secretin in rodent models of polycystic kidney and liver disease. Am J Physiol Renal Physiol 303: F1089-F1098, 2012